Segment, Product and Geographic Area Information (Tables)

Certain information by operating segment follows:

	Revenues				R&D Expenses				Earnings(a)
(millions of dollars)	July 3, 2011		July 4, 2010		July 3, 2011		July 4, 2010		July 3, 2011			July 4, 2010
Three Months Ended:
Primary Care	$	5,870	$	5,923	$	304	$	413	$	3,811		$	4,054
Specialty Care and Oncology		4,038		4,118		375		377		2,586			2,729
Established Products and Emerging Markets		4,732		4,980		79		65		2,475			2,924
Animal Health and Consumer Healthcare		1,776		1,571		105		97		514			482
Total reportable segments		16,416		16,592		863		952		9,386			10,189
Nutrition and other business activities(b)		568		540		868		849		(759	)		(728	)
Reconciling Items:
Corporate(c)		––		––		328		375		(1,647	)		(1,654	)
Purchase accounting adjustments(d)		––		––		––		5		(1,736	)		(2,100	)
Acquisition-related costs(e)		––		––		––		––		(595	)		(1,101	)
Certain significant items(f)		––		––		178		––		(658	)		(95	)
Other unallocated(g)		––		––		––		––		(309	)		(585	)
	$	16,984	$	17,132	$	2,237	$	2,181	$	3,682		$	3,926
Six Months Ended:
Primary Care	$	11,311	$	11,789	$	627	$	775	$	7,357		$	8,137
Specialty Care and Oncology		8,276		8,002		722		741		5,459			5,390
Established Products and Emerging Markets		9,277		9,736		135		97		4,965			5,916
Animal Health and Consumer Healthcare		3,503		3,080		207		203		1,003			879
Total reportable segments		32,367		32,607		1,691		1,816		18,784			20,322
Nutrition and other business activities(b)		1,119		1,101		1,724		1,769		(1,481	)		(1,521	)
Reconciling Items:
Corporate(c)		––		––		661		782		(3,307	)		(3,533	)
Purchase accounting adjustments(d)		––		––		––		15		(3,521	)		(4,939	)
Acquisition-related costs(e)		––		––		4		20		(1,170	)		(1,900	)
Certain significant items(f)		––		––		248		––		(1,866	)		(278	)
Other unallocated(g)		––		––		––		––		(639	)		(1,076	)
	$	33,486	$	33,708	$	4,328	$	4,402	$	6,800		$	7,075

(a)	Income from continuing operations before provision for taxes on income.

(b)

Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the research and development costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

(c)	Corporate includes, among other things, administration expenses, interest income/(expense), certain performance-based and all share-based compensation expenses.

(d)	Significant impacts of purchase accounting include charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.

(e)

Acquisition-related costs can include costs associated with acquiring businesses and, integrating and restructuring acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity for additional information).

(f)

Certain significant items are substantive, unusual items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, the impact of certain tax and/or legal settlements and certain asset impairments.

For the second quarter of 2011, certain significant items related to (a) R&D expenses, representing implementation costs and additional depreciation––asset restructuring associated with our cost-reduction and productivity initiatives that are not associated with an acquisition and (b) earnings, including: (i) restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition of $256 million, (ii) charges for certain legal matters of $53 million, (iii) certain asset impairment charges of $332 million and (iv) other charges of $17 million (see Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity and Note 6. Other (Income)/Deductions––Net for additional information).

For the second quarter of 2010, certain significant items related to earnings included: (i) asset impairment charges of $200 million and (ii) other income of $105 million.

For the first six months of 2011, certain significant items related to (a) R&D expenses, representing implementation costs and additional depreciation––asset restructuring associated with our cost-reduction and productivity initiatives that are not associated with an acquisition and (b) earnings, including: (i) restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition of $828 million, (ii) charges for certain legal matters of $525 million, (iii) certain asset impairment charges of $489 million and (iv) other charges of $24 million (see Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity and Note 6. Other (Income)/Deductions––Net for additional information).

For the first six months of 2010, certain significant items included: (i) asset impairment charges of $200 million, (ii) charges for certain legal matters of $142 million, and (iii) other income of $64 million.

(g)	Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.

Significant product revenues follow:

	Three Months Ended				Six Months Ended
(millions of dollars)	July 3, 2011		July 4, 2010		July 3, 2011		July 4, 2010
Revenues from biopharmaceutical products:
Lipitor	$	2,591	$	2,813	$	4,976	$	5,570
Prevnar/Prevenar 13		821		569		1,817		855
Enbrel(a)		914		808		1,784		1,610
Lyrica		908		762		1,734		1,485
Celebrex		622		604		1,213		1,174
Viagra		495		491		965		970
Norvasc		375		422		731		790
Xalatan/Xalacom		291		449		683		871
Zyvox		325		299		644		591
Sutent		296		255		572		514
Premarin family		255		260		490		516
Geodon/Zeldox		258		247		490		501
Detrol/Detrol LA		230		260		455		521
Genotropin		230		233		439		439
Chantix/Champix		190		170		389		359
Vfend		192		207		387		395
Effexor XR		168		621		372		1,337
Zosyn/Tazocin		162		230		341		494
BeneFIX		176		164		340		318
Prevnar/Prevenar (7-valent)		155		331		308		851
Caduet		143		126		285		261
Zoloft		146		144		281		264
Pristiq		147		113		276		223
Medrol		135		113		256		222
Revatio		130		122		253		236
Zithromax/Zmax		114		110		242		213
ReFacto AF/Xyntha		123		98		240		188
Aromasin		95		122		209		250
Aricept(b)		106		103		205		210
Cardura		101		110		197		217
BMP2		101		99		194		197
Rapamune		100		97		189		188
Fragmin		97		84		188		174
Tygacil		75		88		148		172
Protonix		44		174		103		332
Alliance revenues(c)		875		1,061		1,759		2,065
All other biopharmaceutical products		2,454		2,062		4,709		3,954
Total revenues from biopharmaceutical products		14,640		15,021		28,864		29,527
Revenues from other products:
Animal Health		1,055		893		2,037		1,739
Consumer Healthcare		721		678		1,466		1,341
Nutrition		493		476		963		934
Pfizer CentreSource		75		64		156		167
Total revenues	$	16,984	$	17,132	$	33,486	$	33,708

(a)	Outside the U.S. and Canada.

(b)	Represents direct sales under license agreement with Eisai Co., Ltd.

(c)	Enbrel (in the U.S. and Canada), Aricept, Exforge, Rebif and Spiriva.

Revenues by geographic area follow:

	Three Months Ended							Six Months Ended
(millions of dollars)	July 3, 2011		July 4, 2010		% Change			July 3, 2011		July 4, 2010		% Change

Revenues
United States	$	6,700	$	7,333		(9	)	$	13,724	$	14,598		(6	)
Developed Europe(a)		4,265		4,056		5			8,149		8,317		(2	)
Developed Rest of World(b)		2,673		2,693		(1	)		5,219		4,995		4
Emerging Markets(c)		3,346		3,050		10			6,394		5,798		10
Total Revenues	$	16,984	$	17,132		(1	)	$	33,486	$	33,708		(1	)

(a)	Developed Europe region includes the following markets: Western Europe and the Scandinavian countries.

(b)	Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.

(c)	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey.

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References+ Details

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details